-
-
-
-
-
-
-
Prime Medicine publishes clinical data for CGD gene therapy in NEJM
-
-
-
-
-
-
-
Prime Medicine, Inc. (PRME) Tops Q2 EPS by 2c
-
-
-
-
-
-
-
Prime Medicine (PRME) PT Lowered to $6 at Citizens JMP
-
-
-
-
-
-
-
Prime Medicine (PRME) PT Lowered to $16 at Chardan Capital Markets
-
-
-
-
-
-
-
BMO Capital Highlights Favorite Names for 2025 in Biotech
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Prime Medicine (PRME)
-
-
-
-
-
-
-
Prime Medicine, Inc. (PRME) Tops Q2 EPS by 3c
418,399 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

